A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Diffuse Large B Cell Lymphoma
Lymphoma, T-Cell
Mesothelioma, Malignant
Prostatic Neoplasms, Castration-Resistant
Endometrial Cancer
Ovarian Clear Cell Carcinoma
Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Tulmimetostat
DRUG: Enzalutamide

Sponsor

Novartis Pharmaceuticals